These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31428969)

  • 1. Essential thrombocytosis attributed to JAK2-T875N germline mutation.
    Yoshimitsu M; Hachiman M; Uchida Y; Arima N; Arai A; Kamada Y; Shide K; Ito M; Shimoda K; Ishitsuka K
    Int J Hematol; 2019 Nov; 110(5):584-590. PubMed ID: 31428969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
    Turakhia SK; Murugesan G; Cotta CV; Theil KS
    J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence.
    Shide K; Shimoda K; Kamezaki K; Kakumitsu H; Kumano T; Numata A; Ishikawa F; Takenaka K; Yamamoto K; Matsuda T; Harada M
    Leuk Res; 2007 Aug; 31(8):1077-84. PubMed ID: 17011030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of putative noncanonical driver mutations in patients with essential thrombocythemia.
    Arai A; Yoshimitsu M; Otsuka M; Ito Y; Miyazono T; Nakano N; Obama K; Nakashima H; Hanada S; Owatari S; Nakamura D; Tokunaga M; Kamada Y; Utsunomiya A; Haraguchi K; Hayashida M; Fujino S; Odawara J; Tabuchi T; Suzuki S; Hamada H; Kawamoto Y; Uchida Y; Hachiman M; Ishitsuka K
    Eur J Haematol; 2023 Jun; 110(6):639-647. PubMed ID: 36811253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells.
    Chen C; Li F; Ma MM; Zhang S; Liu Y; Yan ZL; Chen W; Cao J; Zeng LY; Wang XY; Xu KL; Wu QY
    Int J Biol Macromol; 2019 Sep; 137():1030-1040. PubMed ID: 31299252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The frequency of JAK2 V617F mutation, expression level of phosphorylated JAK/STATs proteins and their clinical significance in myeloproliferative disorders patients].
    Hu GY; Deng MY; Zhang GS; Luo YY; Zhu JF
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):394-8. PubMed ID: 19951533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis.
    Etheridge SL; Cosgrove ME; Sangkhae V; Corbo LM; Roh ME; Seeliger MA; Chan EL; Hitchcock IS
    Blood; 2014 Feb; 123(7):1059-68. PubMed ID: 24381227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.
    Marty C; Saint-Martin C; Pecquet C; Grosjean S; Saliba J; Mouton C; Leroy E; Harutyunyan AS; Abgrall JF; Favier R; Toussaint A; Solary E; Kralovics R; Constantinescu SN; Najman A; Vainchenker W; Plo I; Bellanné-Chantelot C
    Blood; 2014 Feb; 123(9):1372-83. PubMed ID: 24398328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.
    Medves S; Noël LA; Montano-Almendras CP; Albu RI; Schoemans H; Constantinescu SN; Demoulin JB
    Haematologica; 2011 Oct; 96(10):1406-14. PubMed ID: 21685469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
    Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutated JAK2 signal transduction in human induced pluripotent stem cell (iPSC)-derived megakaryocytes.
    Pawinwongchai J; Jangprasert P; Nilsri N; Israsena N; Rojnuckarin P
    Platelets; 2022 Jul; 33(5):700-708. PubMed ID: 34749590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia.
    Sultan S; Irfan SM
    Asian Pac J Cancer Prev; 2015; 16(16):7327-30. PubMed ID: 26514532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone infarction: A rare complication of essential thrombocytosis with JAK2-V617F mutation.
    Yang Y; Ren Y; Zhang K; Chen M; Chen C
    Eur J Intern Med; 2024 Apr; 122():142-143. PubMed ID: 38245460
    [No Abstract]   [Full Text] [Related]  

  • 18. Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies.
    Veselovska J; Pospisilova D; Pekova S; Horvathova M; Solna R; Cmejlova J; Cmejla R; Belickova M; Mihal V; Stary J; Divoky V
    Leuk Res; 2008 Mar; 32(3):369-77. PubMed ID: 17719087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin exerts multitarget antileukemia activity in JAK2
    Machado-Neto JA; Fenerich BA; Scopim-Ribeiro R; Eide CA; Coelho-Silva JL; Dechandt CRP; Fernandes JC; Rodrigues Alves APN; Scheucher PS; Simões BP; Alberici LC; de Figueiredo Pontes LL; Tognon CE; Druker BJ; Rego EM; Traina F
    Cell Death Dis; 2018 Feb; 9(3):311. PubMed ID: 29472557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
    Bongartz H; Hessenkemper W; Müller C; Fensky M; Fritsch J; Mandel K; Behrmann I; Haan C; Fischer T; Feller SM; Schaper F
    Cell Signal; 2017 Jul; 35():37-47. PubMed ID: 28365441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.